





Simulating Intervention Trials in Infectious Diseases August 24th-25th, 2016 | Seattle, WA Fred Hutchinson Cancer Research Center Thomas Building, Sze Conference Room

DAY 1 - Wednesday, August 24th, 2016

8:30 – 8:35am	Welcome	Betz Halloran Fred Hutch/U Washington
8:40 - 8:55am	Introductions	Marc Lipsitch Harvard Chan School All
	Simulations for Design and Interpretation of Interv Chair: Nicole Basta	vention Trials
9:00 - 9:20am	Why Model Complex Infectious Disease Intervention Trials	Marc Lipsitch Harvard Chan School
9:20 – 9:25am	Discussion	
9:25 – 9:45am	Mathematical Modelling of a Trial of Community-Wide Isoniazid Preventive Therapy for Tuberculosis	Emilia Vynnycky London School of Hygiene and Tropical Medicine
9:45 – 9:50am	Discussion	
9:50 - 10:10am	Aged Based Modeling in Designing HIV Prevention Trials	Ron Brookmeyer UCLA
10:10 - 10:15am	Discussion	
10:15 - 10:35am	Modeling an HIV Treatment-as- Prevention Trial in Botswana	George Seage Harvard Chan School
10:35 - 10:40am	Discussion	
10:40am	Coffee	

Discussion



11:10am





12:40 - 1:45pm





Stepped Wedge Designs *Chair: Steve Bellan*

11:40 – 12:00pm	Experience with a SW Trial of an Intervention Designed to Prevent Chlamydia and Gonorrhea in Washington State (Treatment)	James Hughes University of Washington
12:00 – 12:05pm	Discussion	
12:05 – 12:15pm	Simulating a Stepped-Wedge Design with an SIS model	Tom Smith Swiss TPH
12:20 - 12:40pm	Discussion	

Lunch











Trial Desiderata: Speed, Efficiency, Accuracy and Ethics

Chair: Alessandro Vespignani

1:45 – 2:05pm	Quantitative Approaches to Assessing Ethical Tradeoffs in Study Design	Steve Bellan University of Texas and University of Georgia
2:05 – 2:10pm	Discussion	
2:10 - 2:30pm	Design and Analysis of Cluster Randomized Vaccine Trials for Emerging Infectious Disease Emergencies	Ira Longini University of Florida
2:30 - 2:35pm	Discussion	
2:35 – 2:55pm	Clinical Trial Designs for Investigational Treatments of Ebola Virus Disease	Ben Cooper Mahidol-Oxford Research Unit and University of Oxford
3:00pm	Discussion	
3:20pm	Coffee	











Pathogen Diversity

Chair: Marc Lipsitch

3:50 - 4:10pm

Predicting Overall Vaccine
Efficacy in a New Setting by ReCalibrating Baseline Covariate
and Immune Response Endpoint
Effect Modifiers of
Genotype/Phenotype-Specific
Vaccine Efficacy

Peter Gilbert Fred Hutch/U Washington

4:10 - 4:15pm

Discussion

4:15 - 4:35pm

Optimal estimation of serotypespecific and overall vaccine efficacy against pneumococcal carriage **Kari Auranen** THL and University of Turku, Finland

4:40pm

Discussion

5:10pm

Adjourn

5:45 pm

Pre-dinner gathering
Art Marble 21

6:30pm

Hosted Dinner/Continued
Discussion,
Art Marble 21
731 Westlake Ave North

http://www.artmarble21.com/











DAY 2 - Thursday, August 25th, 2016

Network Effects and Spillovers as Estimands and Nuisances (I)

Chair: Betz Halloran

8:40 – 9:15am	Measuring Spillover Effects Through the Randomized Saturation Design	Sarah Baird George Washington University Berk Özler , World Bank
9:15 - 9:20am	Discussion	
9:20 – 9:40am	Mysteries and Challenges in Measuring the Effectiveness of OCV	Justin Lessler Johns Hopkins Bloomberg School of Public Health
9:40 – 9:45am	Discussion	
9:45 – 9:55am	Modeling Contamination Between Arms in Cluster- Randomised Trials of Vector Control Intervention	Tom Smith Swiss TPH
10:00am	Discussion	
10:30am	Coffee	











Network effects and spillovers as estimands and nuisances (II) ${\it Chair: Ron\ Brookmeyer}$

10:45 –11:05am	Leveraging Contact Network Structure in the Design of Cluster Randomized Trials	Jukka-Pekka Onnela Harvard Chan School
11:05 – 11:10am	Discussion	
11:10 - 11:30am	Network Science Perspective to the Design and Analysis of Cluster Randomized Trials	Victor DeGruttola Harvard Chan School
11:35 - 11:50am	Discussion	
11:50-12:15pm	Closing, Discussion of Next Steps	Betz Halloran Fred Hutch/U Washington
12:20pm	Adjourn	



